

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

PE/Cyanine7 anti-mouse CD274 (B7-H1, PD-L1)

RRID:AB_10643573

Type: Antibody

Proper Citation

BioLegend Cat# 124314, RRID:AB_10643573

Antibody Information

URL: http://antibodyregistry.org/AB_10643573

Proper Citation: BioLegend Cat# 124314, RRID:AB_10643573

Target Antigen: CD274

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse CD274 (B7-H1, PD-L1)

Description: This monoclonal targets CD274

Target Organism: mouse

Clone ID: Clone 10F.9G2

Antibody ID: AB_10643573

Vendor: BioLegend

Catalog Number: 124314

Alternative Catalog Numbers: 124313

Record Creation Time: 20250820T000528+0000

Record Last Update: 20250820T072047+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse CD274 (B7-H1, PD-L1).

No alerts have been found for PE/Cyanine7 anti-mouse CD274 (B7-H1, PD-L1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. Cell reports. Medicine, 102532.

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. Cell reports. Medicine, 6(6), 102141.

Hirade K, et al. (2025) Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy. Cell reports. Medicine, 6(9), 102317.

Lecky DAJ, et al. (2025) Interferon- γ and IL-27 positively regulate type 1 regulatory T cell development during adaptive tolerance. iScience, 28(5), 112308.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer cell, 43(3), 503.

Gui L, et al. (2025) Targeting the mevalonate pathway potentiates NIAK1 inhibition-induced immunogenic cell death and antitumor immunity. Cell reports. Medicine, 6(2), 101913.

Pereira P, et al. (2025) Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy. Cell reports, 44(3), 115388.

Ravi VR, et al. (2025) Lung CD4+ resident memory T cells use airway secretory cells to stimulate and regulate onset of allergic airway neutrophilic disease. Cell reports, 44(3), 115294.

Broderick C, et al. (2025) A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. Cancer discovery, 15(8), 1717.

Nater M, et al. (2025) Hepatic iNKT cells facilitate colorectal cancer metastasis by inducing a fibrotic niche in the liver. iScience, 28(5), 112364.

Mirji G, et al. (2025) Aromatic microbial metabolite hippuric acid enhances inflammatory responses in macrophages via TLR-MyD88 signaling and lipid remodeling. *Cell reports*, 45(1), 116749.

Guak H, et al. (2024) Transcriptional programming mediated by the histone demethylase KDM5C regulates dendritic cell population heterogeneity and function. *Cell reports*, 43(8), 114506.

Borrelli C, et al. (2024) Stress-free single-cell transcriptomic profiling and functional genomics of murine eosinophils. *Nature protocols*.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. *Cell reports. Medicine*, 5(2), 101397.

Leca J, et al. (2023) IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. *Cancer cell*, 41(2), 323.

Linde IL, et al. (2023) Neutrophil-activating therapy for the treatment of cancer. *Cancer cell*, 41(2), 356.

Li H, et al. (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. *Cancer cell*, 40(1), 36.

Hailemichael Y, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. *Cancer cell*, 40(5), 509.

Asrir A, et al. (2022) Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. *Cancer cell*, 40(3), 318.

Cousin N, et al. (2021) Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8+ T-cell Responses. *Cancer research*, 81(15), 4133.